Platelet rich concentrates, gels and releasates have been used as topical treatments for many years. Platelets contain a large number of growth factors and cytokines, which when released are thought to stimulate the process of wound healing.
Since 2012, CMS has covered autologous platelet-rich plasma (PRP) for patients with chronic non-healing diabetic wounds, pressure wounds and venous wounds under Coverage with Evidence Development (CED).
CMS received a complete, formal request from Nuo Therapeutics to reconsider the NCD. CMS will complete a thorough review of published evidence to determine if the use of autologous platelet rich plasma in patients with chronic non-healing pressure ulcers, venous ulcers and diabetic foot ulcers is reasonable and necessary under the Medicare program.
CMS is soliciting public comment relevant to the reconsideration. We are particularly interested in comments that include scientific evidence and that address the breadth of the request.